Similar articles

• Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

  Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G. Ciardiello F, et al. Clin Cancer Res. 2004 Jan 15;10(2):784-93. doi: 10.1158/1078-0432.ccr-1100-03. Clin Cancer Res. 2004. PMID: 14760102
• Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

  Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M. Lyros O, et al. Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137. Int J Cancer. 2010. PMID: 20039326
• Two targets, one drug for new EGFR inhibitors.

  McNeil C. McNeil C. J Natl Cancer Inst. 2006 Aug 16;98(16):1102-3. doi: 10.1093/jnci/djj350. J Natl Cancer Inst. 2006. PMID: 16912259 No abstract available.
• Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.

  Lee D. Lee D. Clin Lung Cancer. 2005 Sep;7(2):89-91. doi: 10.1016/S1525-7304(11)70394-1. Clin Lung Cancer. 2005. PMID: 16179094 Review. No abstract available.
• Vandetanib therapy in medullary thyroid cancer.

  Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D. Grabowski P, et al. Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Drugs Today (Barc). 2012. PMID: 23170308 Review.